RNAZ Transcode Therapeutics, Inc.

CIK 0001829635 38 ready 8-Ks latest June 1, 2026, 8:59 AM ET RSS · JSON

Ready 8-Ks 38

Latest filing June 1, 2026, 8:59 AM ET

Top materiality 0.90

Event mix other_material ×23 · regulatory ×6 · other ×4

Sentiment 8 pos · 12 neg · 18 neu

Recent 8-K filings for RNAZ

Highest-materiality recent filing

TransCode acquires ABCJ from CK Life Sciences unit; raises $25M in concurrent investment

October 8, 2025, 7:59 PM ET M&A materiality 0.90 positive item 1.01 item 5.03 item 9.01

Acquired 100% of ABCJ from DEFJ (CK Life Sciences sub) for 83,285 common and 1,152.9568 Series A Preferred shares.
Concurrent investment: DEFJ buys 223.7337 Series B Preferred at $111,740/share, raising ~$25M ($20M cash + $5M promissory note at 4% due Jan 2026).

Read filing →

June 1, 2026, 8:59 AM ET other materiality 0.20 neutral item 5.08

TransCode Therapeutics sets July 2, 2026 annual meeting; proposal deadline June 11

Annual meeting scheduled for July 2, 2026; record date May 28, 2026.
May 26, 2026, 6:43 AM ET regulatory materiality 0.80 negative item 3.01

TransCode Therapeutics receives Nasdaq deficiency notice for low stockholders' equity

Stockholders' equity reported at $1.25M as of March 31, 2026, below Nasdaq's $2.5M minimum.
May 22, 2026, 4:15 PM ET regulatory materiality 0.80 negative item 3.01

TransCode Therapeutics receives Nasdaq deficiency notice for low stockholders' equity of $1.25M vs $2.5M minimum

Stockholders' equity as of March 31, 2026 was $1,251,427, below Nasdaq's $2,500,000 minimum requirement.
April 7, 2026, 7:59 PM ET other material materiality 0.75 neutral item 1.01 item 2.03 item 3.02 item 7.01 item 9.01

TransCode secures up to $20M flexible financing from Yorkville via SEPA and convertible notes

Up to $14M SEPA for common stock sales at 97% of lowest 3-day VWAP; up to $6M in pre-paid convertible notes at 5% discount.
March 3, 2026, 6:59 PM ET M&A materiality 0.65 positive item 3.02 item 8.01 item 3.03 item 5.03 item 7.01 item 9.01

TransCode acquires exclusive license to oncolytic immunotherapy platform in all-stock deal

Issued 1,136,364 shares of Series C non-voting convertible preferred to Unleash; convertible to common after stockholder approval.
February 23, 2026, 6:59 PM ET other material materiality 0.30 neutral item 7.01 item 9.01

TransCode publishes preclinical RIG-I agonist data in Molecular Imaging and Biology

Manuscript published Feb 19, 2026 in Molecular Imaging and Biology.
February 5, 2026, 6:59 PM ET other material materiality 0.70 neutral item 7.01 item 9.01

TransCode submits IND amendment for Phase 2a trial of TTX-MC138 in colorectal cancer

IND amendment filed with FDA for Phase 2a dose-expansion trial of TTX-MC138 in colorectal cancer patients with ctDNA-positive MRD.
January 6, 2026, 6:59 PM ET other material materiality 0.70 positive item 7.01 item 9.01

TransCode publishes preclinical data showing TTX-MC138 improves survival in glioblastoma models

Study in Journal of Functional Biomaterials shows TTX-MC138 delivered to GBM tumors after IV injection.
December 23, 2025, 6:59 PM ET M&A materiality 0.65 negative item 9.01 item 8.01

TransCode files ABCJ financials; acquired co's accumulated deficit $193M, DEFJ holds 90.8% voting power

ABCJ (parent of Polynoma) reported 2024 net loss of $16.4M and accumulated deficit of $193M.
December 22, 2025, 6:59 PM ET leadership materiality 0.40 neutral item 5.02 item 7.01 item 9.01

TransCode Therapeutics appoints Jack Stover to Board of Directors

Jack Stover appointed to Board effective Dec 19, 2025; joins Audit and Nominating Committees.
December 11, 2025, 6:59 PM ET other material materiality 0.65 positive item 7.01 item 9.01

TransCode partners with Quantum Leap for Phase 2a trial of TTX-MC138 in colorectal cancer

Collaboration with Quantum Leap to evaluate TTX-MC138 in PRE-I-SPY Phase 2a dose-expansion trial.
October 27, 2025, 7:59 PM ET other material materiality 0.45 neutral item 3.03 item 5.03 item 9.01

TransCode amends preferred stock terms: caps conversion at 19.9% of Oct 8 common, removes delisting conversion right

Filed Amended and Restated Certificate of Designation for Series A and B Preferred on Oct 27, 2025.
October 17, 2025, 7:59 PM ET other material materiality 0.60 neutral item 1.01 item 9.01

TransCode Therapeutics creates CVRs entitling holders to 50% of net proceeds from TTX-MC138 asset sales

Each share of common stock held as of Oct 20, 2025 receives one CVR; CVRs pay 50% of Net Proceeds from future Upfront or Milestone payments on TTX-MC138 program disposals.
October 14, 2025, 7:59 PM ET other material materiality 0.75 positive item 8.01 item 9.01

TransCode completes Phase 1a of TTX-MC138; 44% stable disease rate, moves to Phase 2a

16 patients treated across 4 dose levels; no dose-limiting toxicities or significant safety events observed.
October 8, 2025, 7:59 PM ET M&A materiality 0.90 positive item 1.01 item 5.03 item 9.01

TransCode acquires ABCJ from CK Life Sciences unit; raises $25M in concurrent investment

Acquired 100% of ABCJ from DEFJ (CK Life Sciences sub) for 83,285 common and 1,152.9568 Series A Preferred shares.
October 8, 2025, 7:59 PM ET M&A materiality 0.80 neutral item 1.01 item 5.03 item 2.01 item 3.02 item 3.03 item 5.02 item 7.01 item 9.01

TransCode acquires ABCJ, gets $25M investment from DEFJ, appoints new CEO

Acquired 100% of ABCJ for 83,285 common shares (9.99% of pre-close), convertible preferred, and up to $95M milestone payments.
October 3, 2025, 7:59 PM ET other material materiality 0.50 neutral item 1.01

TransCode Therapeutics amends MGH license; milestone payments doubled to $2.95M per patent family

Second Amendment to Exclusive Patent License Agreement with Massachusetts General Hospital, effective August 15, 2025.
September 2, 2025, 7:59 PM ET other materiality 0.15 neutral item 5.07

TransCode shareholders elect directors and approve stock plan increase at 2025 annual meeting

Elected directors Philippe Calais, Thomas Fitzgerald, Erik Manting, Magda Marquet; each received >84K votes for.
June 13, 2025, 7:59 PM ET other materiality 0.10 neutral item 5.08

TransCode sets 2025 annual meeting Aug 29; proposal deadline June 23

2025 Annual Meeting scheduled for August 29, 2025; record date July 11, 2025.
May 7, 2025, 7:59 PM ET regulatory materiality 0.80 negative item 3.01

TransCode receives Nasdaq delisting notice; plans to appeal bid-price deficiency

Company received Nasdaq notice on May 6, 2025 for failing to maintain $1.00 minimum bid price for 30 consecutive days (Mar 24–May 5).
May 5, 2025, 7:59 PM ET other material materiality 0.60 neutral item 3.03 item 5.03 item 7.01 item 9.01

TransCode Therapeutics announces 1-for-28 reverse stock split effective May 15, 2025

Reverse split at 1-for-28 ratio; effective 12:01 a.m. ET on May 15, 2025.
May 2, 2025, 7:59 PM ET other material materiality 0.65 negative item 5.07 item 7.01 item 9.01

TransCode Therapeutics announces 1-for-28 reverse stock split to regain Nasdaq compliance

Stockholders approved 1-for-28 reverse split on May 2, 2025; board ratified the ratio.
April 21, 2025, 7:59 PM ET other material materiality 0.55 neutral item 5.07 item 8.01 item 9.01

TransCode adjourns special meeting due to lack of quorum; reconvenes May 2 for reverse split vote

Only 12.73% of outstanding shares voted at April 21 special meeting; quorum required one-third.
March 25, 2025, 7:59 PM ET other material materiality 0.75 negative item 1.01 item 8.01 item 9.01

TransCode announces $10M registered direct offering of 10.25M shares and warrants at $0.98/unit

Gross proceeds of ~$10M from sale of 10.25M shares and 10.25M warrants at $0.98/unit.
February 25, 2025, 6:59 PM ET other material materiality 0.45 neutral item 5.07 item 8.01 item 9.01

TransCode shareholders approve warrant adjustments and share issuance at special meeting

Proposal One approved: full issuance of shares upon exercise of Series C and D warrants with floor price of $2.4882.
February 4, 2025, 6:59 PM ET other material materiality 0.40 neutral item 5.07 item 8.01 item 9.01

TransCode Therapeutics adjourns special meeting; only 29.94% of shares voted, below quorum

Special meeting held Feb 4, 2025 lacked quorum (needs one-third of outstanding shares); only 29.94% voted.
December 20, 2024, 6:59 PM ET other material materiality 0.65 positive item 8.01 item 9.01

TransCode opens Phase 1 Cohort 3; PK/PD from Cohort 1 show 66% miR-10b inhibition at 24h

Safety Review Committee approved third cohort after no significant safety/DLTs in Cohort 2.
December 2, 2024, 6:59 PM ET other material materiality 0.70 positive item 1.01 item 3.02 item 7.01 item 8.01 item 9.01

TransCode raises ~$8M in private placement; expects to regain Nasdaq compliance

Issued 21.2M shares/pre-funded warrants, 21.2M Series C and 21.2M Series D warrants at $0.377/unit.
November 29, 2024, 6:59 PM ET other material materiality 0.60 neutral item 3.03 item 5.03 item 7.01 item 9.01

TransCode Therapeutics announces 1-for-33 reverse stock split effective Dec 4, 2024

Reverse split ratio 1-for-33; effective 12:01 a.m. ET Dec 4, 2024; new CUSIP 89357L402.
November 25, 2024, 6:59 PM ET other material materiality 0.65 neutral item 5.07

TransCode shareholders approve 10M share offering and reverse stock split at special meeting

Ratified issuance of 10M shares of common stock and warrants to ThinkEquity LLC via best-efforts public offering.
November 6, 2024, 6:59 PM ET regulatory materiality 0.85 negative item 3.01 item 9.01

TransCode gets Nasdaq extension to regain compliance; Public Reprimand issued

Nasdaq Hearings Panel granted extension to comply with Bid Price Rule 5550(a)(2), Equity Rule 5550(b), and Shareholder Approval Rule 5635(d).
September 27, 2024, 7:59 PM ET regulatory materiality 0.85 negative item 3.01

Nasdaq notifies TransCode of shareholder approval violation; adds to delisting risk

Received new Nasdaq deficiency letter on Sep 23, 2024 for failing to obtain shareholder approval for a deeply discounted offering.
August 28, 2024, 7:59 PM ET other material materiality 0.90 negative item 8.01

TransCode Therapeutics faces Nasdaq delisting over bid price and equity deficiencies; hearing Oct 1

Minimum Bid Price Deficiency Letter received Aug 13; stock below $1.00 for 30 consecutive days through Aug 12.
August 16, 2024, 7:59 PM ET other material materiality 0.85 negative item 3.01

TransCode receives two Nasdaq deficiency notices; faces potential delisting

On Aug 13, 2024, Nasdaq notified TransCode of minimum bid price deficiency; stock closed below $1.00 for 30 consecutive days.
July 24, 2024, 7:59 PM ET other material materiality 0.65 neutral item 1.01 item 3.02 item 8.01 item 9.01

TransCode Therapeutics prices $3.0M public offering of 10M shares at $0.30

Offering of 10,000,000 common shares at $0.30 per share for gross proceeds of $3.0M.
June 14, 2024, 7:59 PM ET other materiality 0.65 negative item 5.07

TransCode Therapeutics shareholders reject reverse stock split proposal at annual meeting

Reverse stock split proposal failed: 1,018,164 for, 1,277,915 against, 96,498 abstain.
June 13, 2024, 7:59 PM ET other material materiality 0.75 negative item 5.07

TransCode shareholders reject reverse stock split; stock plan amendment approved

Reverse stock split (1:2 to 1:40) failed: 1,018,164 for, 1,277,915 against, 96,498 abstain.
June 7, 2024, 7:59 PM ET regulatory materiality 0.45 positive item 8.01

TransCode Therapeutics regains Nasdaq minimum bid price compliance; hearing cancelled

Received Nasdaq letter on June 3, 2024 confirming compliance with Listing Rule 5550(a)(2).

Materiality & sentiment trend

Max materiality 0.90 · Median 0.65 · Most common event other_material

8 positive 12 negative 18 neutral

source · RNAZ on sec.gov